14th Alzheimer's and Parkinson's Drug Development Summit

The approval of the first anti-amyloid drugs has resurrected the neurodegenerative disease space, opening the door for enhanced competition and innovation to develop novel disease-modifying therapies. However, as challenges remain in the clinical adoption of Lecanemab and Donanemab, the field needs to navigate the move towards disease-modifying therapeutics.
 
Capitalizing on the surge of innovation across new targets, lessons learned from clinical setbacks, groundbreaking progress in blood-based diagnostics, and more, the 14th Alzheimer’s and Parkinson’s Drug Development Summit returns as the only industry-focused and end-to-end meeting, with comprehensive coverage spanning early discovery through to late clinical and regulatory.